Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Ocumension Therapeutics
歐康維視生物
(Incorporated in the Cayman Islands with limited liability)
(Stock code: 1477)

VOLUNTARY ANNOUNCEMENT
ACCEPTANCE OF APPLICATION FOR DRUG REGISTRATION OF DOMESTICALLY PRODUCED DEXAMETHASONE INTRAOCULAR SUSPENSION

This announcement is made by Ocumension Therapeutics (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to keep the shareholders of the Company and potential investors informed of the latest business updates of the Group.

The board of directors (the "**Board**") of the Company is pleased to announce that the application for drug registration of dexamethasone intraocular suspension has been accepted by the Center for Drug Evaluation of the National Medical Products Administration (the "**NMPA**") of the People's Republic of China (the "**PRC**") as a Class 4 chemical drug. Dexamethasone intraocular suspension is a variety of OT-502 (DEXYCU®, Shishu (視妹®)), a key drug of the Group, to be produced domestically by way of technology transfer. The product has applied for inclusion in the list of priority review varieties of the CDE, and the public notification procedure has been completed.

DEXYCU® is a single-dose, sustained-release suspension of dexamethasone, a corticosteroid, indicated for the treatment of postoperative ocular inflammation. In June 2026, the new drug application (the "**NDA**") for DEXYCU® was approved by the NMPA, marking a key milestone in its commercialization pathway. To date, the product supplied to the PRC market has been manufactured overseas and imported into the PRC in accordance with the terms of such NDA.

Upon approval of the registration application, the Group will be able to produce dexamethasone intraocular suspension in Chinese Mainland by way of technology transfer of OT-502, in place of overseas manufacturing and importation. The Board believes that localized production is expected to (i) enhance the stability, security and timeliness of the supply in the PRC market, thereby reducing the Group's reliance on overseas production and importation processes; and (ii) reduce the production costs of the product and the related import and transportation costs, thereby optimizing its cost structure and supporting its long-term commercial development.

Cautionary Statement: The acceptance of the registration application by the NMPA does not guarantee that approval will be granted, and the timing and outcome of the review remain uncertain. **Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board
Ocumension Therapeutics
Dr. Lian Yong CHEN
Chairman and Non-executive Director

Hong Kong, September 1, 2026

As of the date of this announcement, the Board comprises Mr. Ye LIU and Dr. Zhaopeng HU as executive Directors, Dr. Lian Yong CHEN, Mr. Yanling CAO and Dr. Qin XIE as non-executive Directors, and Ms. Beibei ZHUANG, Mr. Yiran HUANG and Mr. Zhenyu ZHANG as independent non-executive Directors.